By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Stocks > Second judge says US not liable in Moderna COVID-19 vaccine patent case
Stocks

Second judge says US not liable in Moderna COVID-19 vaccine patent case

News Room
Last updated: 2023/04/30 at 11:28 AM
By News Room
Share
3 Min Read
SHARE

© Reuters. FILE PHOTO: Vial labelled “Moderna coronavirus disease (COVID-19) vaccine” placed on displayed Moderna logo is seen in this illustration picture taken March 24, 2021. REUTERS/Dado Ruvic/Illustration

By Blake Brittain

(Reuters) – Moderna (NASDAQ:) Inc failed to persuade a Delaware federal judge on Wednesday to shift liability from the company to the U.S. government for alleged patent infringement by Moderna’s COVID-19 vaccine.

Chief Judge Colm Connolly’s ruling for Alnylam Pharmaceuticals Inc came just over a month after a different judge in Delaware rejected Moderna’s similar motion in another vaccine patent lawsuit.

Connolly did not include the reasoning for his decision in his order, which he announced from the bench following arguments in the case.

A Moderna spokesperson said in a statement that the company “respectfully disagrees” with the decision and is confident that discovery will support its position. Representatives for Alnylam did not immediately respond to a request for comment.

Cambridge, Massachusetts-based Alnylam sued both Moderna and Pfizer Inc (NYSE:) in Delaware last year, seeking royalties for the lipid nanoparticle (LNP) technology their vaccines use to deliver genetic material known as mRNA.

The cases are part of a wave of patent lawsuits that have been filed over technology used in the COVID-19 shots, including one filed by Moderna against Pfizer last year.

Moderna said in the Alnylam case that the court should dismiss claims that were based on vaccines it sold to the U.S. government and that Alnylam should instead seek damages from the government itself. It cited a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One.

Moderna made the same argument in a motion to dismiss part of another patent lawsuit brought by Arbutus Biopharma (NASDAQ:) Corp and Genevant Sciences GmbH.

U.S. District Judge Mitchell Goldberg rejected Moderna’s motion in that case last year and said it had not yet proven the government was more than an “incidental beneficiary” of the shots.

Goldberg denied the motion for a second time last month after the federal government backed Moderna’s position.

Read the full article here

News Room April 30, 2023 April 30, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Hedge fund trader at heart of cum-ex scandal extradited to Denmark

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Bank CEOs to warn lawmakers against proposal to boost capital

The CEOs of America’s top banks are on Wednesday expected to speak…

Vladimir Putin praises relations with UAE on first stop of Gulf tour 

Stay informed with free updatesSimply sign up to the Middle Eastern politics…

How to Use Options to Get ‘Conditional Dividends’

Tyros and market idiots, of which there are an unlimited, replenishing number,…

UK watchdog bans adverts by three airlines over ‘misleading’ environmental claims

Stay informed with free updatesSimply sign up to the Airlines myFT Digest…

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

Earnings call: Perimeter Solutions reports Q3 2023 earnings, addresses mild fire season impact and inventory destocking

By News Room
Stocks

Earnings call: Bioventus Inc. reports third quarter earnings, outperforms expectations, and raises annual guidance

By News Room
Stocks

Earnings call: Angel Oak Mortgage REIT reports strong Q3 2023 performance, focuses on growth

By News Room
Stocks

Earnings call: Adeia’s Q3 2023 results show strong deal momentum, revenue guidance narrowed

By News Room
Stocks

Earnings call: TELA Bio reports robust Q3 2023 results, projects strong YoY growth

By News Room
Stocks

Earnings call: Runway Growth Finance announces robust Q3 2023 results and optimistic outlook

By News Room
Stocks

Earnings call: Nikon raises revenue forecast, adjusts operating profit amid mixed business performance

By News Room
Stocks

Earnings call: TELA Bio reports robust Q3 2023 results, eyes continued growth

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?